Effects of disopyramide and flecainide on the kinetics of inward rectifier potassium channels in rabbit heart muscle.
1. Standard patch-clamp techniques were used to study the interaction of therapeutic concentrations of flecainide and disopyramide with single inwardly-rectifying potassium channels in cell-attached membrane patches from rabbit ventricular myocytes. 2. Under drug-free conditions, the potassium channels had a conductance of 31 +/- 2 pS (n = 13), a mean open time of 230 +/- 6 ms (n = 11) recorded at the resting cell potential, and an open probability of 0.66 +/- 0.20 (n = 39). The resting potential of the cells studied was -68.5 +/- 3.6 mV (n = 32). 3. Disopyramide did not reduce the open probability of the channel when the cell was voltage-clamped at the resting cell potential. However, disopyramide increased the mean open time of the channel, recorded at the resting cell potential, by 15% at 5 microM and by 29% at 20 microM. The action potential prolonging actions of disopyramide in therapeutic concentrations appear not to be due to blocking the inward rectifier K+ channel. 4. Flecainide (3.0 microM, but not at 0.5 microM) decreased the open probability without changing the conductance of the channel, at 3 microM (51.0 +/- 7.2%, n = 6, P = 0.03) at the resting cell potential. Flecainide increased the mean open time of the channel, recorded at the resting cell potential, by 12% at 3.0 microM. 5. We propose that flecainide stabilized the inward rectifier K+ channel in an inactivated state, without plugging the conducting pore. In addition, it appeared to bind to an open conformation of the channel,since some of the reduction in open probability could be accounted for by the lengthening of the mean open time. The changes in open-state kinetics suggest that this binding may be in the region of the activation gate.
Martin
D K
DK
Department of Cardiology, St. Vincent's Hospital, Sydney, N.S.W., Australia.
Nakaya
Y
Y
Wyse
K R
KR
Campbell
T J
TJ
D000818:Animals; D002462:Cell Membrane / Q000378:metabolism / Q000502:physiology; D004206:Disopyramide / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005424:Flecainide / Q000494:pharmacology*; D006321:Heart / Q000187:drug effects* / Q000502:physiology; D006352:Heart Ventricles / Q000187:drug effects / Q000648:ultrastructure; D066298:In Vitro Techniques; D007700:Kinetics; D008297:Male; D008564:Membrane Potentials / Q000187:drug effects; D009206:Myocardium / Q000378:metabolism / Q000648:ultrastructure; D015221:Potassium Channels / Q000187:drug effects* / Q000502:physiology; D011817:Rabbits; D016276:Ventricular Function
D015221:Potassium Channels; D004206:Disopyramide; D005424:Flecainide